We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
- Authors
Haluska, Paul; Worden, Frank; Olmos, David; Yin, Donghua; Schteingart, David; Batzel, Gretchen N; Paccagnella, M Luisa; de Bono, Johann S; Gualberto, Antonio; Hammer, Gary D
- Abstract
Insulin-like growth factor 1 receptor signaling through upregulation of the stimulatory ligand IGF-II has been implicated in the pathogenesis of adrenocortical carcinoma. As there is a paucity of effective therapies, this dose expansion cohort of a phase 1 study was undertaken to determine the safety, tolerability, pharmacokinetics, and effects on endocrine markers of figitumumab in patients with adrenocortical carcinoma.
- Publication
Cancer chemotherapy and pharmacology, 2010, Vol 65, Issue 4, p765
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-009-1083-9